Thai investigators test a botanical emulgel formulation to identify early safety signals related to skin irritation and allergenicity before advancing to patient trials.
A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
As Trump’s health officials push personal responsibility, critics warn their rhetoric blames patients, shapes policy, and risks deepening health inequalities.
KFF Health News
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
New research has documented 4 cases of lip basal cell carcinoma presenting as smooth yellow nodules—a rare clinical presentation that may be mistaken for benign mesenchymal tumors, potentially resulting in diagnostic delays and postponed treatment.
A new multicenter trial found that self-injected low-dose triamcinolone using an assistance device was as effective and safe as physician-administered injections for inflammatory acne, with improved outcomes at higher doses for severe lesions.